You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石四藥集團(02005.HK)上半年純利達2.47億港元 中期息維持派5港仙
格隆匯 08-25 12:27

格隆匯8月25日丨石四藥集團(02005.HK)公佈,截至2020年6月30日止6個月,集團實現銷售收入17.83億港元;毛利11.41億港元,毛利率為64.0%;公司股權持有人應占溢利2.47億港元;每股基本盈利0.0815港元,宣派中期股息每股0.05港元,和去年同期持平。

報告期內,來自靜脈輸液的收益為11.83億港元,其中,非PVC軟袋及直立式軟袋輸液的收益分別為6.15億港元及1.59億港元,總額為7.74億港元,佔靜脈輸液的收益65.4%;PP塑瓶輸液的收益為2.97億港元,佔靜脈輸液的收益25.1%;玻璃瓶輸液的收益為1.12億港元,佔靜脈輸液的收益9.5%。

另一方面,鑑於高端安瓿注射產品具有高增長潛力,集團特別緻力於推廣有關產品。因此,安瓿注射液的收益為2.94億港元(2019年6月30日:1.51億港元),較去年同期增加94.8%。其他產品及服務的收益為2.53億港元(2019年6月30日:1.21億港元),較去年同期增加108.4%,主要由於原料藥及鹽酸阿比多爾膠囊的銷售顯著增加。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account